REN and type 1 diabetes mellitus: Particularly in T1D prevalent users the use of lipid modifying agents (index vs 2019: 34.9% vs 48.8%), beta blocking agents (19.1% vs 24.7%), calcium channel blockers (15.9 vs 22.5%), and renin‐angiotensin system medication (41.2% vs 49.5%) increased.